Edition:
United States

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

10.38EUR
4:56am EDT
Change (% chg)

€-0.18 (-1.70%)
Prev Close
€10.56
Open
€10.56
Day's High
€10.60
Day's Low
€10.31
Volume
25,642
Avg. Vol
93,817
52-wk High
€20.90
52-wk Low
€8.30

Latest Key Developments (Source: Significant Developments)

Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros
Friday, 30 Mar 2018 10:02am EDT 

March 30 (Reuters) - NANOBIOTIX SA ::TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016.CASH AVAILABLE AT DECEMBER 31, 2017 AMOUNTS TO EUR 47.2M..FY NET LOSS EUR ‍​26.1 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.2018 SHOULD BE ANOTHER YEAR OF GROWTH.FY CORE OPERATING LOSS EUR 24.9 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA IN Q2 2018..  Full Article

Nanobiotix FY Revenue Down At ‍​0.3 Million Euros
Wednesday, 28 Feb 2018 12:46pm EST 

Feb 28 (Reuters) - NANOBIOTIX SA ::FY REVENUE EUR ‍​0.3 MILLION VERSUS EUR 1.6 MILLION YEAR AGO.TO PRESENT RESULTS OF SOFT TISSUE SARCOMA PHASE II/III TRIAL WITH NBTXR3 IN Q2 2018‍​.TO START IN Q2 2018 PHASE I/II CLINICAL TRIAL OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH ANTI-PD1 ANTIBODY IN CANCER PATIENTS‍​.  Full Article

Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers
Thursday, 11 Jan 2018 02:07am EST 

Jan 11 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS.COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR.WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S..HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND.  Full Article

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 12:44pm EST 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology
Monday, 13 Nov 2017 02:02am EST 

Nov 13 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PRESENTED NEW CLINICAL AND PRE-CLINICAL DATA CONFIRMING NBTXR3'S SIGNIFICANT POTENTIAL ROLE IN IMMUNO-ONCOLOGY AT SITC ANNUAL MEETING.‍PATIENTS TREATED WITH NBTXR3 AND RADIOTHERAPY SHOW A MARKED INCREASE OF PD1 AND CD8 INFILTRATION​.‍NBTXR3 ACTIVATED BY RADIOTHERAPY INDUCES SIGNIFICANT ADAPTIVE IMMUNE PATTERN VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH SOFT TISSUE SARCOMA​.‍STRONG DATA TO SUPPORT RATIONAL FOR UPCOMING CLINICAL TRIAL IN COMBINATION WITH CHECK POINT INHIBITORS​.‍PRECLINICAL DATA ON DIFFERENT ANIMAL MODELS CONFIRM BROAD POTENTIAL OF NBTXR3 AS A PRIMER OF IMMUNE RESPONSE​.  Full Article

Nanobiotix completes new share issue for about 27.2 million euros
Tuesday, 31 Oct 2017 03:07am EDT 

Oct 31 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES.‍ISSUES OF 1,941,789 NEW SHARES, PAR VALUE EUR 0.03​.‍ISSUE PRICE OF NEW SHARES HAS BEEN SET AT EUR 14.00 PER SHARE, REPRESENTING AN 18% DISCOUNT​.‍TRADING OF THE NEW SHARES TO START ON EURONEXT PARIS ON NOVEMBER 2, 2017​.  Full Article

Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3
Monday, 23 Oct 2017 02:00am EDT 

Oct 23 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA.‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​.‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​.  Full Article

Nanobiotix H1 net loss widens to 12.2 million euros
Thursday, 31 Aug 2017 01:29pm EDT 

Aug 31 (Reuters) - NANOBIOTIX SA ::H1 TOTAL REVENUE OF CIRCA EUR 1.9M (H1 2016: EUR 3.0M).H1 NET LOSS EUR 12.2 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO.H1 CORE OPERATING LOSS EUR 11.8 MILLION VERSUS LOSS OF EUR 10.1 MILLION YEAR AGO.CASH BALANCE AS OF 30 JUNE 2017 REACHES EUR 31M AS PER EXPECTATIONS..  Full Article

Nanobiotix Q2 revenue down at 58,645 euros
Wednesday, 12 Jul 2017 01:18pm EDT 

July 12 (Reuters) - NANOBIOTIX SA ::Q2 REVENUE EUR 58,645 VERSUS EUR 936,319 YEAR AGO.H1 RENTAL REVENUE EUR 91.5 MLN VS EUR 91.4 MLN YR AGO.  Full Article

Nanobiotix says Phase I/II head and nack cancer trial shows promising results
Monday, 5 Jun 2017 12:00pm EDT 

June 5 (Reuters) - NANOBIOTIX SA :NANOBIOTIX : PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING.NANOBIOTIX : PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING.‍7 OUT 9 PATIENTS HAD COMPLETE REPONSE AT 10% DOSE LEVEL OR MORE​.FOLLOW UP SHOWS A POTENTIAL IMPACT ON LONG TERM DISEASE CONTROL.‍AMENDMENT FILED FOR A DOSE EXPANSION COHORT OF 44 ADDITIONAL PATIENTS​.‍PLAN TO OPEN THIS STUDY IN UNITED STATES​.‍VERY GOOD SAFETY PROFILE WITH NO AES AND SAES IN STAGE III/IV IN FRAIL PATIENTS OLDER THAN 70 YEARS OLD​.  Full Article

BRIEF-Nanobiotix Did Not Generate Any Revenue In Q1

* ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED